PHARMACEUTICAL COMPOSITION COMPRISING VALSARTAN
The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.
1 . A pharmaceutical composition comprising valsartan, alone or in combination with at least another therapeutic agent in the presence of a pharmaceutically acceptable carrier for the prevention or treatment of Atrial fibrillation (AF) in patients having heart failure.
2 . Use of a pharmaceutical composition comprising valsartan, alone or in combination with at least another therapeutic agent in the presence of a pharmaceutically acceptable carrier for the preparation of a medicament for the prevention or treatment of AF in patients having heart failure.
3 . A method for preventing or reducing the incidence of AF in patients with heart failure comprising administering a therapeutically effective amount of a pharmaceutical composition comprising valsartan, alone or in combination with at least another therapeutic agent in the presence of a pharmaceutically acceptable carrier.
4 . The method of claim 3 , wherein valsartan is administered in a daily dose of from about 80 mg to about 320 mg.
5 . A method of reducing morbidity or mortality in a patient having heart failure comprising administering a therapeutically effective amount of valsartan, alone or in combination with at least another therapeutic agent in the presence of a pharmaceutically acceptable carrier.
6 . Pharmaceutical composition, use, method according to any of the preceding claims wherein the therapeutic agent is selected from the group consisting of anti-hypertensive agents, anti-obesity agents, anti-diabetic agents, beta-blockers, inotropic agents and hypolipidemic agents.
7 . Pharmaceutical composition, use, method according to claim 6 , wherein the anti-hypertensive agent is an ACE inhibitor.
8 . Pharmaceutical composition, use, method according to claim 7 , wherein valsartan is combined with an ACE inhibitor and a beta-blocker.